~~<i id='AD0A7DCB5B'><strike id='AD0A7DCB5B'><tt id='AD0A7DCB5B'><pre id='AD0A7DCB5B'></pre></tt></strike></i>~~

Home» explore» entertainment

entertainment

author：focus 2025-09-30 09:04:52 Page View：965

The Roche booth at ESMO in Madrid. — Roche's booth at the 2023 ESMO conference. Andrew Joseph/STAT

MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday.

The findings, which Roche is planning to submit to regulators, could give patients with early-stage ALK-positive cancers another option. The standard treatment after surgery for these patients is chemotherapy.

The results from the Alina trial were presented here at the annual meeting of the European Society for Medical Oncology.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Why Medicare shouldn’t cover every FDA
Next article： Anesthesiologist group: stop taking Ozempic before surgery

focus

BioMarin wins approval for gene therapy to treat hemophilia A

AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

EthanMiller/GettyImagesWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbio

Apple is now the first public company to be valued at $3 trillion

6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

Medicare drug price negotiation legal challenge met with skepticism

AdobeWILMINGTON,Del.—Wednesdaywasthefirsttimethatafederaljudgeaskedquestionsin-personofdrugindustryl